Fulcrum Therapeutics (NASDAQ:FULC) executives highlighted what they described as strong physician interest and encouraging clinical signals from the company’s PIONEER study in sickle cell disease during a recent discussion hosted by Leerink Partners equity research analyst Joe Schwartz. PIONEER takeaways: HbF induction, hemolysis markers, and early VOC signal Chief Executive Officer Alex Sapir said feedback […]